ABIOMED INC Form 8-K June 15, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report: June 10, 2005

(Date of earliest event reported)

ABIOMED, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation) 04-2743260 (IRS Employer Identification Number)

0-20584

(Commission File Number)

22 Cherry Hill Drive Danvers, MA 01923

(Address of Principal Executive Offices, including Zip Code)

(978) 777-5410

(Registrant s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Principal Officers

Departure of Directors or Principal Officers; Election of Directors Appointment of

On June 10, 2005, David M. Lederman, Ph.D. resigned as Chairman of the Board of Directors and as a Director of ABIOMED, Inc. On June 15, 2005, we issued a press release announcing the resignation of Dr. Lederman and also announcing that Michael R. Minogue, President and Chief Executive Officer, will assume the additional role of Chairman of the Board of Directors. The full text of the press release is attached as exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits

(c) Exhibits

Exhibit Number Description

99.1 Press release dated June 15, 2005

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABIOMED, Inc.

By: /s/ Charles B. Haaser

Charles B. Haaser Controller

Principal Accounting Officer Principal Financial Officer

Date: June 15, 2005

3

Controller 11

EXHIBIT INDEX

Exhibit Number Description

99.1 Press release dated June 15, 2005

4

Controller 12